Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.
The drug maker says it has spoken to Deen about her racist comments, but an opaque company statement indicates the Danish firm has not cut ties with the now-former Food Network star.
An Abbott iPhone app is drawing attention to the practice of compensating bloggers for app reviews, as some call into question the ethics of pay-for-play online PR.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.